Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/9/2018
SIETES contiene 92557 citas

 
 
 1 a 20 de 43 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. FDA approves first drug to treat smallpox. DIA Daily 2018:1. [Ref.ID 102674]
2. Cita con resumen
Swetlitz I. Gottlieb pushes back against criticism of ‘breakthrough’ designation. STAT Daily Recap 2018:5. [Ref.ID 102595]
3.Enlace a cita original Cita con resumen
Webster P. Pimavanserin evaluated by the FDA. Lancet 2018;391:5 de mayo. [Ref.ID 102594]
4. Cita con resumen
Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]
5.
Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]
6. Cita con resumen
Hamel MB. Speed, safety, and industry funding — From PDUFA I to PDUFA VI. N Engl J Med 2017;377:2278-86. [Ref.ID 102166]
7. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
10. Cita con resumen
Huang Z, Ma J. Chronic purulent nasal discharge. BMJ 2017;357:j2061. [Ref.ID 101636]
11. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
12. Cita con resumen
Schick A, Miller KL, Lanthier M, Pan GD, Nardinelli C. Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals. Drug Saf 2017:24 de marzo. [Ref.ID 101505]
14. Cita con resumen
Anónimo. FDA grants priority review to Novartis’ leukemia drug. DIA Daily 2016:2. [Ref.ID 100923]
16. Cita con resumen
Anónimo. FDA grants accelerated approval to olaratumab to treat advanced STS. DIA Daily 2016:2. [Ref.ID 100834]
17. Cita con resumen
Anónimo. FDA accepts NDA for valbenazine, grants priority review. DIA Daily 2016:4. [Ref.ID 100806]
19. Cita con resumen
Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]
20.Tiene citas relacionadas Cita con resumen
Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74. [Ref.ID 100614]
Seleccionar todas
 
 1 a 20 de 43 siguiente >>